Year 2021 / Volume 28 / Supplement 1

Article Osteoarthritis Monographic

Review of the pharmacological treatment of osteoarthritis pain with paracetamol, non-steroid anti-inflammatory (NSAIDSS) and selective cyclooxygenase-2 inhibitors (COXIB)

Rev. Soc. Esp. Dolor. 2021; 28(13): 43-48 / DOI: 10.20986/resed.2021.3864/2020

Mercè Matute, Antonio Montero


ABSTRACT

In this monograph, a review of all aspects related to osteoarthritis is carried out in order to offer the patient with osteoarthritis the most optimal management in light of the bibliography available at the time of writing.
In this specific article, we made a bibliographic review of the pharmacological treatment of osteoarthritis with paracetamol, classical non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase type 2 inhibitors (COXIBS).
We update the aspects that interest us most from a clinical point of view: efficacy, safety, comparison within these options and with the rest of the alternatives (interventional or other pharmacological) for being able to decide the patient profiles in which this type is indicated of pharmacological options, the evolutionary moment of the disease or even the maintenance time of this type of drug.
For reaching our objective, we have carried out a bibliographic review of the studies evaluating the effect of these analgesic drugs in osteoarthritis with an electronic search using Google Scholar, Medline/PubMed and the Cochrane database of systematic reviews to compile the available literature between the years 2000 and 2020.



RESUMEN

En este monográfico se realiza una revisión de todos los aspectos relacionados con la artrosis para poder ofrecer al/la paciente el manejo más óptimo a la luz de la bibliografía disponible en el momento de redacción del mismo.
En este artículo en concreto realizamos una revisión bibliográfica del tratamiento farmacológico de la artrosis con paracetamol, antinflamatorios no esteroideos clásicos (AINE) e inhibidores selectivos de la ciclooxigenasa tipo 2 (COXIB).
Actualizamos los aspectos que más nos interesan desde un punto de vista clínico: eficacia, seguridad, comparativa dentro de estas opciones y con el resto de alternativas (intervencionistas u otras farmacológicas), para poder decidir los perfiles de pacientes en los que puede estar indicado este tipo de opciones farmacológicas, el momento evolutivo de su enfermedad o incluso el tiempo de mantenimiento de este tipo de fármacos.
Para ello hemos realizado una revisión bibliográfica de los estudios que evalúan el efecto de estos fármacos analgésicos en la artrosis mediante una búsqueda electrónica utilizando Google Scholar, Medline/PubMed y la base de datos Cochrane de revisiones sistemáticas con el fin de recopilar la literatura disponible entre los años 2000 y 2020.





Complete Article

Nuevo comentario

Security code:
CAPTCHA code image
Speak the codeChange the code
 

Comentarios

No comments in this article

Bibliografía

1. Apostu D, Lucaciu O, Mester A, Oltean-Dan D, Baciut M, Baciut G, et al. Systemic drugs with impact on osteoarthritis. Drug Metab Rev. 2019;51(4):498-523. DOI: 10.1080/03602532.2019.1687511.
2. Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014;71(1):11-23.
3. Onakpoya IJ. Paracetamol as first line for treatment of knee and hip osteoarthritis. BMJ Evid Based Med. 2020;25(1):40. DOI: 10.1136/bmjebm-2019-111213.
4. McCrae JC, Morrison EE, MacIntyre IM, Dear JW, Webb DJ. Long-term adverse effects of paracetamol - a review. Br J Clin Pharmacol. 2018;84(10):2218-30. DOI: 10.1111/bcp.13656.
5. Smith HS. Potential analgesic mechanisms of acetaminophen. Pain Physician. 2009;12(1):269-80.
6. Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016;75(3):552-9. DOI: 10.1136/annrheumdis-2014-206914.
7. Przybyła GW, Szychowski KA, Gmiński J. Paracetamol - An old drug with new mechanisms of action. Clin Exp Pharmacol Physiol. 2020. DOI: 10.1111/1440-1681.13392.
8. De Coster O, Forget P, De Mey J, Van Schuerbeek P, Poelaert J. Identification of the cerebral effects of paracetamol in healthy subjects: an fMRI study. Br J Pain. 2020;14(1):23-30. DOI: 10.1177/2049463719854483.
9. McCrae JC, Morrison EE, MacIntyre IM, Dear JW, Webb DJ. Long-term adverse effects of paracetamol - a review. Br J Clin Pharmacol. 2018;84(10):2218-30. DOI: 10.1111/bcp.13656.
10. Price C. NICE forced into U-turn on advice to avoid paracetamol in osteoarthritis [Internet]. Pulse Today. (consultado el 8 de enero de 2018). Available at http://www.pulsetoday.co.uk/clinical/more-clinical-areas/ musculoskeletal/nice-forced-into-u-turn-on-advice-to-avoid- paracetamol-in-osteoarthritis/20005837.article
11. Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CW, Day RO, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350:h1225. DOI: 10.1136/bmj.h1225.
12. Leopoldino AO, Machado GC, Ferreira PH, Pinheiro MB, Day R, McLachlan AJ, et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst Rev. 2019;2(2):CD013273. DOI: 10.1002/14651858.CD013273.
13. Aweid O, Haider Z, Saed A, Kalairajah Y. Treatment modalities for hip and knee osteoarthritis: A systematic review of safety. J Orthop Surg (Hong Kong). 2018;26(3):2309499018808669. DOI: 10.1177/2309499018808669.
14. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149-62. DOI: 10.1002/acr.24131.
15. da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090):e21-e33. DOI: 10.1016/S0140-6736(17)31744-0.
16. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-89. DOI: 10.1016/j.joca.2019.06.011.
17. Geenen R, Overman CL, Christensen R, Åsenlöf P, Capela S, Huisinga KL, et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(6):797-807. Doi: 10.1136/annrheumdis-2017-212662.
18. Lee K, Cooke J, Cooper G, Shield A. Move it or Lose it. Is it Reasonable for Older Adults with Osteoarthritis to Continue to Use Paracetamol in Order to Maintain Physical Activity? Drugs Aging. 2017;34(6):417-23. DOI: 10.1007/s40266-017-0450-1.
19. Girard P, Sourdet S, Cantet C, de Souto Barreto F, Rolland Y. Acetaminophen Safety: Risk of Mortality and Cardiovascular Events in Nursing Home Residents, a Prospective Study. J Am Geriatr Soc. 2019;67(6):1240-7. DOI: 10.1111/jgs.15861.
20. Sheehan WJ, Mauger DT, Paul IM, Moy JN, Boehmer SJ, Szefler SJ, et al. Acetaminophen versus ibuprofen in young children with mild persistent asthma. N Engl J Med. 2016;375(7):619-30. DOI: 10.1056/NEJMoa1515990.
21. Conaghan PG, Arden N, Avouac B, Migliore A, Rizzoli R. Safety of Paracetamol in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):7-14. DOI: 10.1007/s40266-019-00658-9.
22. Watelet J, Laurent V, Bressenot A, Bronowicki JP, Larrey D, Peyrin-Biroulet L. Toxicity of chronic paracetamol ingestion. Aliment Pharmacol Ther. 2007;26(11-12):1543-6. DOI: 10.1111/j.1365-2036.2007.03503.x.
23. Bretherick AD, Craig DG, Masterton G, Bates C, Davidson J, Martin K, et al. Acute liver failure in Scotland between 1992 and 2009; incidence, aetiology and outcome. QJM. 2011;104(11):945-56. DOI: 10.1093/qjmed/hcr098.
24. Majeed MH, Sherazi SAA, Bacon D, Bajwa ZH. Pharmacological Treatment of Pain in Osteoarthritis: A Descriptive Review. Curr Rheumatol Rep. 2018;20(12):88. DOI: 10.1007/s11926-018-0794-5.
25. Theken KN, Hersh EV, Lahens NF, Lee HM, Li X, Granquist EJ, et al. Variability in the Analgesic Response to Ibuprofen Is Associated With Cyclooxygenase Activation in Inflammatory Pain. Clin Pharmacol Ther. 2019;106(3):632-41. DOI: 10.1002/cpt.1446.
26. Chou R, McDonagh MS, Nakamoto E, Griffin J. Analgesics for osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Oct. Report No.: 11(12)-EHC076-EF.
27. Lanas A, Benito P, Alonso J, Hernández-Cruz B, Barón-Esquivias G, Perez-Aísa A, et al. Recomendaciones para una prescripción segura de antiinflamatorios no esteroideos: documento de consenso elaborado por expertos nominados por 3 sociedades científicas (SER-SEC-AEG). Reumatol Clin. 2014;10(2):68-84. DOI: 10.1016/j.reuma.2013.10.004.
28. Kloppenburg M, Kroon FP, Blanco FJ, Doherty M, Dziedzic KS, Greibrokk E, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16-24. DOI: 10.1136/annrheumdis-2018-213826.
29. Katz JN, Smith SR, Collins JE, Solomon DH, Jordan JM, Hunter DJ, et al. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. Osteoarthritis Cartilage. 2016;24(3):409-18. DOI: 10.1016/j.joca.2015.10.006.
30. Rasmussen S. NSAIDs are superior to paracetamol for osteoarthritic pain and function in a network meta-analysis. BMJ Evid Based Med. 2018;23(1):40-1. DOI: 10.1136/ebmed-2017-110878.
31. Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P. Celecoxib for osteoarthritis. Cochrane Database Syst Rev. 2017;5(5):CD009865. DOI: 10.1002/14651858.CD009865.pub2.
32. da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090):e21-e33. DOI: 10.1016/S0140-6736(17)31744-0.
33. Lee K, Cooke J, Cooper G, Shield A. Move it or Lose it. Is it Reasonable for Older Adults with Osteoarthritis to Continue to Use Paracetamol in Order to Maintain Physical Activity? Drugs Aging. 2017;34(6):417-23. DOI: 10.1007/s40266-017-0450-1.
34. Tenti S, Giordano N, Mondanelli N, Giannotti S, Maheu E, Fioravanti A. A retrospective observational study of glucosamine sulfate in addition to conventional therapy in hand osteoarthritis patients compared to conventional treatment alone. Aging Clin Exp Res. 2020;32(6):1161-72. DOI: 10.1007/s40520-019-01305-4.

Artículos relacionados

Effects of hydrotherapy on pain in osteoarthritis and fibromyalgia: a narrative review

Rev. Soc. Esp. Dolor. 2022; 29(2): 78-87 / DOI: 10.20986/resed.2022.3955/2021

Genicular nerve radiofrequency in osteoarthritis-related chronic knee pain

Rev. Soc. Esp. Dolor. 2021; 28(3): 154-168 / DOI: 10.20986/resed.2021.3900/2021

Postoperative ketamine efficacy in patients receiving chronic opioids undergoing spinal surgery

Rev. Soc. Esp. Dolor. 2021; 28(2): 92-99 / DOI: 10.20986/resed.2021.3825/2020

Interventional management of osteoarthritic pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 85-90 / DOI: 10.20986/resed.2021.3853/2020

Platelet rich plasma and intra-articular mesenchymal stem cells in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 80-84 / DOI: 10.20986/resed.2021.3858/2020

Intra-articular botulinum toxin and ozone in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 73-79 / DOI: 10.20986/resed.2021.3857/2020

Infiltrations of steroids and hyaluronic acid in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 64-72 / DOI: 10.20986/resed.2021.3854/2020

New pharmacological targets for osteoarthritis induced pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 57-63 / DOI: 10.20986/resed.2021.3863/2020

Opioids in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 49-56 / DOI: 10.20986/resed.2021.3855/2020

News in the clinical practice guidelines regarding the treatment of the hip, knee and hands osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 38-42 / DOI: 10.20986/resed.2021.3870/2020

Central sensitization in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 31-37 / DOI: 10.20986/resed.2021.3876/2020

Experimental models for pain evaluation in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 18-30 / DOI: 10.20986/resed.2021.3872/2020

Ethiopathogenic mechanism of osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 11-17 / DOI: 10.20986/resed.2021.3851/2020

Epidemiology, clinical impact and therapeutic objectives in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 4-10 / DOI: 10.20986/resed.2021.3874/2020

Osteoarthritis and pain: the complexity and impact of a symptom

Rev. Soc. Esp. Dolor. 2021; 28(13): 1-3 / DOI: 10.20986/resed.2021.3886/2021

Effectiveness and current recommendation of manual therapy on hip osteoarthritis. An overview

Rev. Soc. Esp. Dolor. 2020; 27(6): 375-391 / DOI: 10.20986/resed.2021.3835/2020

Drug consumption used for musculoskeletal pain treatment in a cohort of blue-collar workers in Zaragoza (Spain)

Rev. Soc. Esp. Dolor. 2020; 27(3): 150-159 / DOI: 10.20986/resed.2020.3749/2019

Conventional radiofrequency for genicular nerves in treatment of knee osteoarthritis

Rev. Soc. Esp. Dolor. 2020; 27(1): 59-60 / DOI: 10.20986/resed.2016.3515/2016

New strategies for postoperative pain control in tonsillectomy surgery. Is all that glitters gold?

Rev. Soc. Esp. Dolor. 2019; 26(5): 270-275 / DOI: 10.20986/resed.2019.3742/2019

Non-steroidal anti-inflammatory drugs and cardiovascular safety: is naproxen safer than celecoxib? New evidences

Rev. Soc. Esp. Dolor. 2018; 25(6): 365-367 / DOI: 10.20986/resed.2017.3549/2016

Use of major opioids for control of pain in hospitalized patients

Rev. Soc. Esp. Dolor. 2018; 25(6): 318-324 / DOI: 10.20986/resed.2018.3629/2017

Expenditure, prescription and consumption of analgesic drugs before and during the economic crisis

Rev Soc Esp Dolor 2018; 25(3): 155-162 / DOI: 10.20986/resed.2017.3609/2017

Paxiflas®: new FDT combination of tramadol/paracetamol for treating moderate to severe pain

Rev Soc Esp Dolor 2017; 24(2):59-67 / DOI: 10.20986/resed.2017.3565/2017

Instrucciones para citar

Matute M, Montero A. Review of the pharmacological treatment of osteoarthritis pain with paracetamol, non-steroid anti-inflammatory (NSAIDSS) and selective cyclooxygenase-2 inhibitors (COXIB). Rev Soc Esp Dolor 2021; 28(13): 43-48 / DOI: 1020986/resed20213864/2020


Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 32689 veces.
Este artículo ha sido descargado 9 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Aceptado: 18/01/2021

Publicado: 03/02/2021


Compartir

Este artículo aun no tiene valoraciones.
Reader rating:
Rate this article:
© 2024 Revista de la Sociedad Española del Dolor
ISSN: 1134-8046   e-ISSN: 2254-6189

      Indexada en: